Senegal vs Syrian Arab Republic: Mortality rate attributed to cardiovascular disease, cancer, diabetes
Senegal
21.4
in 2021
Syrian Arab Republic
21.3
in 2021
Senegal rank
71st
Syrian Arab Republic rank
72nd
Mortality rate attributed to cardiovascular disease, cancer, diabetes over time
- Senegal
- Syrian Arab Republic
How they compare
Senegal currently reports 21.4 against 21.3 in Syrian Arab Republic, a difference of 0.1.
The two have swapped places 1 time across 7 shared years of data; in 2000 it was Syrian Arab Republic ahead.
Senegal ranks 71st and Syrian Arab Republic ranks 72nd of 197 countries.
Across the 3 decades both report, Senegal averaged higher in 2 and Syrian Arab Republic in 1.
Head to head by decade
| Decade | Senegal | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 23.9 | 25.8 | 1.9 | Syrian Arab Republic |
| 2010s | 22.73 | 22.23 | 0.5 | Senegal |
| 2020s | 21.9 | 21.8 | 0.1 | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher mortality rate attributed to cardiovascular disease, cancer, diabetes, Senegal or Syrian Arab Republic?
- Senegal, at 21.4 against 21.3 in Syrian Arab Republic as of 2021.
- What is the difference in mortality rate attributed to cardiovascular disease, cancer, diabetes between Senegal and Syrian Arab Republic?
- 0.1, with Senegal ahead.
- How many years of comparable data are there for Senegal and Syrian Arab Republic?
- 7 years are reported by both, from 2000 to 2021.
- How do Senegal and Syrian Arab Republic rank globally for mortality rate attributed to cardiovascular disease, cancer, diabetes?
- Senegal ranks 71st and Syrian Arab Republic ranks 72nd of 197 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease (probability). Statizoid refreshes it automatically from the source and publishes the full history for both places.